Evidence map›Paper›PMID 38934279›Full record

ReviewCurrent medicinal chemistry2025

An Overview of Acridine Analogs: Pharmacological Significance and Recent Developments.

Govindaraj Sabarees, Ganesan Padmini Tamilarasi, Veerachamy Alagarsamy, Subramani Kandhasamy, Siddan Gouthaman, Viswas Raja Solomon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Acridine Derivatives as Antifungal and Antivirulence Agents AgainstInternational journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Govindaraj SabareesDepartment of Pharmaceutical Chemistry, Shri Venkateshwara College of Pharmacy, Ariyur, Puducherry 605102, India.
Ganesan Padmini TamilarasiDepartment of Pharmaceutical Chemistry, Shri Venkateshwara College of Pharmacy, Ariyur, Puducherry 605102, India.
Veerachamy AlagarsamyMedicinal Chemistry Research Laboratory, MNR College of Pharmacy, Greater Hyderabad, Sangareddy 502294, India.
Subramani KandhasamySchool of Mechanical and Electrical Engineering, Quanzhou University of Information Engineering, Quanzhou, Fujian, 362000, China.
Siddan GouthamanOrganic Material Laboratory, Department of Chemistry, Indian Institute of Technology, Roorkee, 247667, India.
Viswas Raja SolomonMedicinal Chemistry Research Laboratory, MNR College of Pharmacy, Greater Hyderabad, Sangareddy 502294, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical effectiveness of the available anticancer drugs has been reduced due to the development of drug resistance and serious adverse effects, which have restricted chemotherapy for cancer. Therefore, there is a persistent need for new anticancer medications with reduced side effects. Medical researchers are pursuing various methods to find new, potent, specifically targeted molecules for cancer treatment. Through various techniques, numerous molecules are discovered. However, among them, acridine stands out as a promising heterocycle that has captured the interest of medicinal chemists and acquired significant pharmacological value. The synthetic adaptability of acridine has enabled the creation of numerous derivatives with a wide range of architectural properties, further accelerating this broad spectrum of pharmacological activities. Recent studies have looked at the mechanisms by which acridine and its analogs inhibit tyrosine kinases, topoisomerases, telomerase, and DNA repair interaction. We have compiled our knowledge of acridine compounds for their anticancer activities, mechanisms of action, structure-activity relationship (SAR), and selective, specific activity against different cancer drug targets, as well as

Indexed as

AcridinesAntineoplastic AgentsNeoplasmsAnimalsHumansStructure-Activity RelationshipTelomeraseAcridinesAntineoplastic AgentsTelomeraseAcridineanticancerDNA intercalationdrug discoverydrug resistance.heterocycletopoisomerase

Identifiers

PMID38934279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.